Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The Impact of Personalized Medicine on Cancer Survival in Years  
  • The overall five-year survival rate for women with invasive breast cancer is now 89 percent.  
  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • Incidence rates for colorectal cancer have been decreasing since 1985, from 66 to 52 per 100,000 in 2002.  
  • Baseline lung cancer screening would lead to more than 130,000 additional survivors in 2012.